Inozyme Pharma, Inc. - Common Stock (INZY)
Frequently Asked Questions About Inozyme Pharma, Inc. - Common Stock (INZY)
Has Inozyme Pharma gone public?
Yes, Inozyme Pharma went public through an initial public offering (IPO) in February 2021, allowing it to raise capital to fund its clinical trials and research initiatives. It trades on the Nasdaq under the ticker symbol INZY.
How does Inozyme Pharma engage with the community and stakeholders?
Inozyme Pharma actively engages with the patient community, healthcare providers, and stakeholders through educational initiatives, collaboration on research, and participation in industry conferences. The company values transparency and strives to build strong relationships with those affected by rare diseases.
How does Inozyme Pharma ensure patient safety during clinical trials?
Inozyme Pharma prioritizes patient safety during its clinical trials by adhering to strict regulatory guidelines, implementing comprehensive monitoring protocols, and engaging independent review boards. Patient well-being is paramount, and the company is committed to ethical standards in research.
How does INZ-701 work?
INZ-701 works by providing a therapeutic replacement for the deficient enzyme in patients with ENPP1 deficiency. By enhancing the activity of the enzyme, it helps regulate phosphate levels and improve calcification processes in the body, which can lead to better patient outcomes.
What are ENPP1 and its role in the body?
ENPP1, or ecto-nucleotide triphosphate diphosphohydrolase-1, is an enzyme that plays a crucial role in the metabolism of extracellular nucleotides. It is essential for regulating phosphate levels in tissues and preventing pathological calcification.
What are the financial strategies of Inozyme Pharma?
Inozyme Pharma employs a financial strategy that emphasizes sustainable growth through a combination of IPO proceeds, strategic partnerships, and grants. This approach allows the company to fund its research and development while advancing toward profitable commercialization.
What are the pipeline products of Inozyme Pharma?
Inozyme Pharma has a robust pipeline that includes INZ-701 for ENPP1 deficiency, as well as other investigational therapies targeting related lysosomal storage disorders. The company is continually exploring additional targets in order to expand its therapeutic offerings.
What does Inozyme Pharma, Inc. do?
Inozyme Pharma, Inc. is a clinical-stage biopharmaceutical company focused on developing transformative therapies for patients with rare diseases caused by deficiencies in lysosomal enzymes. The company's innovative approach aims to improve treatment for conditions like ENPP1 deficiency and other related metabolic disorders.
What future developments can we expect from Inozyme Pharma?
Looking ahead, Inozyme Pharma plans to advance its pipeline with ongoing clinical trials for INZ-701 and potential new product candidates. The company is dedicated to expanding its research in lysosomal storage disorders and hopes to bring additional therapies to market in the coming years.
What is the lead product candidate of Inozyme Pharma?
Inozyme Pharma's lead product candidate is INZ-701, an investigational therapy designed to treat patients with ENPP1 deficiency, which is a rare metabolic disorder that can lead to calcification of tissues. The drug aims to address the underlying enzyme deficiency and alleviate symptoms.
What is the long-term vision of Inozyme Pharma?
Inozyme Pharma's long-term vision is to become a leader in the development of therapies for rare diseases, particularly those caused by lysosomal enzyme deficiencies. The company aims to expand its pipeline over time and make a meaningful impact on the lives of patients with unmet medical needs.
What is the mission of Inozyme Pharma?
Inozyme Pharma's mission is to develop innovative, life-altering therapies for patients suffering from rare diseases associated with lysosomal enzyme deficiencies. The company is dedicated to improving the quality of life for these patients through cutting-edge scientific research and development.
What is the significance of the Nasdaq listing for Inozyme Pharma?
Being listed on the Nasdaq provides Inozyme Pharma with increased visibility and credibility in the marketplace, facilitating access to capital that supports its research and development initiatives. It also enables investors to more easily trade the company's shares.
What is the status of INZ-701 in clinical trials?
As of now, INZ-701 is undergoing clinical trials, with safety and efficacy being assessed in patients with ENPP1 deficiency. The trials are designed to evaluate the drug's potential benefits and inform its next regulatory steps.
What kind of investors does Inozyme Pharma attract?
Inozyme Pharma attracts a diverse range of investors, including institutional investors, venture capital firms focused on biotechnology, and individual investors interested in supporting innovative therapies for rare diseases. The company's promising pipeline and clinical progress make it an appealing investment opportunity.
When was Inozyme Pharma, Inc. founded?
Inozyme Pharma, Inc. was founded in 2018 by a team of experienced scientists and business leaders with a commitment to advancing novel treatments for rare diseases. The company is headquartered in Boston, Massachusetts.
Where is Inozyme Pharma located?
Inozyme Pharma is headquartered in Boston, Massachusetts, a hub for biotechnology and pharmaceutical research. This strategic location allows the company to collaborate with various academic institutions and bio-innovation companies in the region.
Who are Inozyme Pharma's main competitors?
Inozyme Pharma operates in a competitive landscape populated by other biotechnology companies developing therapies for rare diseases, particularly those focused on lysosomal storage disorders. Notable competitors include companies like Alexion Pharmaceuticals and Amicus Therapeutics.
Who are the key founders of Inozyme Pharma?
Inozyme Pharma was co-founded by a team including President and CEO Yvonne Greenstreet, who has extensive experience in the biopharmaceutical industry, and Chief Scientific Officer Dr. Ranjit Nair. Their leadership brings a wealth of knowledge in drug development and commercialization.
What is the current price of Inozyme Pharma, Inc. - Common Stock?
The current price of Inozyme Pharma, Inc. - Common Stock is 3.950
When was Inozyme Pharma, Inc. - Common Stock last traded?
The last trade of Inozyme Pharma, Inc. - Common Stock was at 4:00 pm EDT on May 16th, 2025
What is the market capitalization of Inozyme Pharma, Inc. - Common Stock?
The market capitalization of Inozyme Pharma, Inc. - Common Stock is 243.83M
How many shares of Inozyme Pharma, Inc. - Common Stock are outstanding?
Inozyme Pharma, Inc. - Common Stock has 61.73M shares outstanding.